Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Scientific Oral Presentations (Best of Scientific Oral)

Otology/Neurotology

Session: Best of Scientific Oral Presentations 1

The Effect of Angiotensin Receptor Blockade Using Losartan in Otoprotection Against Noise-Induced Hearing Loss

Saturday, September 28, 2024
1:36 PM – 1:42 PM EDT
Location: MBCC, 222
Disclosure(s):
Carolina Chu, MS:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Miles J. Klimara, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Douglas M. Bennion, MD, PhD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Introduction: Noise trauma impairs cochlear microcirculation through a variety of mechanisms resulting in hearing loss. Losartan, an angiotensin II receptor antagonist, is anti-inflammatory and vasoprotective in acute and chronic diseases of the heart, kidneys, and brain, and is a promising candidate treatment in attenuating noise-induced hearing loss.

Methods: CBA/J mice (age 9-10 weeks, n=4-7 per group) were randomized to standard or losartan-infused chow (20 mg/kg/day, ~100 mg daily dose in humans) starting three days prior to exposure to two hours of 8-16k octave band noise at 102.5dB SPL (males)/105dB SPL (females) for temporary threshold shifts or 105dB SPL (males)/107.5dB SPL (females) for permanent threshold shifts. Auditory brainstem responses (ABR) were recorded up to two weeks after noise exposure. Cochleae were whole-mounted and immunostained for inner hair cell (IHC) synapse counting. Studies were conducted from 07/2023-01/2024.

Results: One day after moderate-intensity noise exposure, losartan treatment blunted temporary ABR threshold shifts (p < 0.02) at 16kHz (16 vs. 5dB SPL shift in control and losartan-treated animals respectively) and 32kHz (18 vs. 1dB SPL shift). ABR thresholds returned to baseline by 14 days post-exposure. However, the control group had fewer mean synapses per IHC relative to the losartan-treated group (15.3 vs. 19.9 synapses/IHC, p< 0.02). In a second cohort, one day after high-intensity noise exposure, losartan again blunted ABR threshold increases (p < 0.02), a protective effect that persisted to 14 days with significantly (p < 0.05) lower permanent threshold shifts with losartan treatment at 8kHz (15 vs. 2dB SPL shift), 16kHz (33 vs. 5dB SPL shift), 32kHz (19 vs. 0dB SPL shift), and click stimulus (18 vs. 4dB SPL shift). Additionally, losartan resulted in significantly improved ABR wave 1 latencies and amplitude growth function compared to control at 14 days (p < 0.05).

Conclusions: Losartan provides an otoprotective effect against both temporary and permanent ABR threshold shifts after noise overexposure and exhibits protection against noise-induced cochlear synaptopathy.

    Presenting Author(s)

  • Carolina Chu, MS

    Medical Student
    University of Iowa, Carver College of Medicine
    Coralville, Iowa, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Co-Author(s)

  • TK

    Tanner J. Kempton, MD

    Resident
    University of Iowa, Department of Otolaryngology
    Iowa City, IA, United States

    Disclosure information not submitted.

  • Peter Eckard, BS

    Medical Student
    Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences
    Little Rock, Arkansas, United States

    Disclosure information not submitted.

  • RH

    Rong Zhuo Hua, BS

    Student
    University of Iowa, United States

    Disclosure information not submitted.

  • BH

    Bryce Hunger, BS

    Student
    University of Iowa, United States

    Disclosure information not submitted.

  • MK

    Miles J. Klimara, MD

    Resident Physician
    University of Iowa Hospitals & Clinics
    Iowa City, IA, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Senior Author(s)

  • MH

    Marlan R. Hansen, MD

    Professor and Chair
    Univ of Iowa
    Iowa City, IA, United States

    Disclosure information not submitted.

  • Douglas M. Bennion, MD, PhD

    Neurotology Fellow
    University of California San Diego
    Iowa City, IA, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.